You are here

RT002

Settle down, Allergan investors. Botox's market share is safe, analysts say

Fierce Pharma

Wed, 12/6/17 - 11:11 am

wrinkle treatment

Watch out Allergan: Revance’s wrinkle-reducer beats Botox in PhIII trials

Endpoints

Tue, 12/5/17 - 09:31 am

clinical trials

wrinkle treatments

The new Biotech Scorecard: 10 make-or-break industry events for the fourth quarter

Stat

Tue, 10/3/17 - 11:50 am

Axovant Sciences

SAGE Therapeutics

Global Blood Therapeutics

DBV Technologies

Amicus Therapeutics

Spark Therapeutics

Revance Therapeutics